Pharmacokinetics in Drug Development: Regulatory and Development Paradigms. Vol. 2

Contributor(s):

Material type: Text

TextPublication details: Arlington American Association of Pharmaceutical Scientists 2004Description: 488pISBN:

9780971176737

Subject(s):

Pharmacokinetics

DDC classification:

615.7 PHA

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Item location	Collection	Call number	Status	Date due	Barcode	Item holds
Reference Book	NIMA Knowledge Centre	6th Floor Silence Zone	Reference	615.7 PHA (Browse shelf(Opens below))	Not For Loan		P0004965

Total holds: 0

Browsing Institute of Pharmacy shelves, Collection: Reference Close shelf browser (Hides shelf browser)

Previous	No cover image available	No cover image available	No cover image available		No cover image available	No cover image available	No cover image available	Next
Previous	615.7 PAT Formulation Development and Optimization of Delayed Release Mini-Tablets in Capsule Dosage Form Containing BCS Class I Drug	615.7 PAT Formulation Development and Optimization of Delayed Release Mini-Tablets in Capsule Dosage Form Containing BCS Class I Drug	615.7 PAT A Review on ALS as Motor Neurodegeretive Disposition	615.7 PHA Pharmacokinetics in Drug Development: Regulatory and Development Paradigms. Vol. 2	615.7 PUN Formulation and Charaterization of Fixed Dose Combination of Rifampicin and Isoniazid: A Novel Approach to Improve Stability and Bioavailability	615.7 PUN Formulation and Charaterization of Fixed Dose Combination of Rifampicin and Isoniazid: A Novel Approach to Improve Stability and Bioavailability	615.7 SAN Formulation Development of Extended Release Tablet Containing Anti-Muscaranic Agent	Next

These volumes are designed to be the most complete guide to pharmacokinetics (PK) and its role in drug development. The volumes fill a gap between the academic science and the practical application of that knowledge in drug development. Volume 1 discusses the role that PK plays in selected clinical study designs. Volume 2 details the key regulatory and development paradigms in which PK supplements decision-making during drug development.

There are no comments on this title.

to post a comment.